Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Learn more about:
Related Clinical Trial
Three-dimensional Ultrasonography Thyroid Volume Measurement. Oral AMXT 1501 Dicaprate in Combination With IV DFMO Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Official Title

Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers

Brief Summary

      This phase II trial studies the effect of selpercatinib given before surgery in treating
      patients with thyroid cancer whose tumors have RET alterations (changes in the genetic
      material [deoxyribonucleic acid (DNA)]). Selpercatinib may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth. Giving selpercatinib before surgery may
      help shrink the tumors and help control the disease.

Detailed Description


      I. To evaluate the efficacy of neoadjuvant selpercatinib in medullary thyroid cancer by
      objective response rate (ORR) per RECIST (standard Response Evaluation Criteria in Solid
      Tumors [RECIST]).


      I. To evaluate the efficacy of neoadjuvant selpercatinib in medullary thyroid cancer by ORR
      per modified neck RECIST.

      II. To evaluate the efficacy of neoadjuvant selpercatinib in medullary thyroid cancer per
      surgical margin status, which is categorized as R0, R1, and R2 surgical resection.

      III. To evaluate the safety profile of neoadjuvant selpercatinib. IV. To evaluate the
      efficacy of neoadjuvant selpercatinib on progression-free survival (PFS), including overall
      PFS and locoregional PFS.

      V. To measure changes in expected and actual surgical morbidity/complexity as well as
      evaluate changes of R0/R1 resection rates in pre-specified extrathyroidal anatomic target
      interfaces before and after selpercatinib treatment.


      I. In patients with differentiated thyroid cancer [DTC] and anaplastic thyroid cancer [ATC]
      only, to evaluate the efficacy of neoadjuvant selpercatinib by ORR per RECIST (standard
      RECIST and modified neck RECIST), surgical margin status (R0/R1 versus [vs.] R2), safety
      profile, surgical morbidity/complexity, PFS and overall survival (overall survival [OS], ATC

      II. To define and measure changes of patient-reported outcomes and quality of life as
      measured by MD Anderson Symptom Inventory (MDASI) and European Quality of Life Five Dimension
      (EQ-5D) in patients with RET-altered thyroid cancer who receive selpercatinib treatment.

      III. To explore translational endpoints in selpercatinib neoadjuvant therapy with
      biopsies/tissue collection before selpercatinib treatment and during surgery.

      IV. To explore peripheral and tissue measures associated with selpercatinib mechanisms of
      resistance in patients who experience disease progression after selpercatinib treatment.


      Patients receive selpercatinb orally (PO) twice daily (BID) on days 1-28. Treatment repeats
      every 28 days for up to 7 cycles in the absence of disease progression or unacceptable
      toxicity. Patients then undergo standard of care surgery.

      After completion of study treatment, patients are followed up for disease progression status
      every 3-4 months for the first 2 years. ATC patients continue follow-up every 6 months for
      year 3 and 4, and once in year 5.

Study Phase

Phase 2

Study Type


Primary Outcome

Objective response rate (ORR)

Secondary Outcome

 R0/R1 resection rates


Malignant Thyroid Gland Neoplasm


Quality-of-Life Assessment

Study Arms / Comparison Groups

 Treatment (selpercatinib)
Description:  Patients receive selpercatinb PO BID on days 1-28. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 26, 2021

Completion Date

September 10, 2024

Primary Completion Date

September 10, 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with RET-altered thyroid cancer who present with locally advanced primary
             tumor, defined as T3 or T4 by imaging or invasive/bulky nodal disease, or with
             recurrent/residual invasive/bulky nodal disease will be enrolled in this trial,
             regardless of whether distant metastases are present or not

          -  At least 12 years of age on the day of signing informed consent

          -  Pathologic findings supporting the clinical impression of medullary thyroid carcinoma,
             papillary thyroid carcinoma, poorly differentiated thyroid carcinoma, or anaplastic
             thyroid carcinoma. Diagnosis of anaplastic thyroid carcinoma may include consistent
             with or suggestive of terminology associated with: anaplastic thyroid carcinoma,
             undifferentiated carcinoma, squamous carcinoma; carcinoma with spindled, giant cell,
             or epithelial features; poorly differentiated carcinoma with pleomorphism, extensive
             necrosis with tumor cells present

          -  Having an activating RET gene alteration (fusion or mutation). The RET alteration
             result should be generated from a laboratory with Clinical Laboratory Improvement Act
             (CLIA), ISO/EIC, College of American Pathologists (CAP), or other similar
             certification that clearly denotes the presence of a RET alteration in tumor, or
             institutional-approved cell free DNA blood test for RET alteration

          -  Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed. The specific
             agent(s), duration of treatment, clinical benefit, and reason for discontinuation
             (e.g., progressive disease [PD], drug toxicity, or intolerance) should be documented
             for all kinase inhibitors the patient has been exposed to

          -  At least one measurable lesion as defined by RECIST 1.1

          -  Surgical morbidity/complexity score of 1 to 4 (moderate, severe, very severe, or

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (age >= 16
             years) or Lansky Performance Score (LPS) >= 40% (age < 16 years) with no sudden
             deterioration 2 weeks prior to study registration

          -  Absolute neutrophil count (ANC) >= 1500/uL

          -  Hemoglobin >= 9 g/dL (5.58 mmol/L)

          -  Platelets >= 100,000/uL

          -  Total bilirubin =< 1.5 X upper limit of normal (ULN) (Except participants with a
             documented history of Gilbert syndrome who must have a total bilirubin < 3 X ULN)

          -  Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) < 2.5 X ULN OR < 5 X
             ULN if the liver has tumor involvement

          -  Normal serum potassium, calcium, and magnesium levels (may be receiving supplements).
             Grade 1 hypocalcemia (corrected serum calcium > 8) is acceptable

          -  Willing to undergo tumor biopsy prior to trial treatment, unless in the opinion of the
             treating physician, a biopsy is not feasible or safe. Subjects must be willing to
             ultimately undergo surgery if their tumor becomes surgically resectable

          -  Ability to comply with outpatient treatment, laboratory monitoring, and required
             clinic visits for the duration of study participation

          -  Willing and able to provide written informed consent signed by study patient (or
             legally acceptable representative if applicable)

          -  Willingness of men with partners of childbearing potential or women of childbearing
             potential to use a highly effective contraceptive method during treatment with study
             drug and for 3 months following the last dose of study drug. Male study participants
             should refrain from sperm donation during study treatment and for up to 6 months
             following the last dose of selpercatinib


          -  Unless not allowed by local regulations, women of childbearing potential who are
             abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or
             in a same-sex relationship (as part of their preferred and usual lifestyle) must agree
             to either remain abstinent or stay in a same-sex relationship without sexual relations
             with males. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post
             ovulation methods), declaration of abstinence just for the duration of the trial, and
             withdrawal are not acceptable methods of contraception

          -  A postmenopausal woman will be defined as having no menses for 12 months without an
             alternative medical cause. Male sterility will be defined as only men sterilized
             surgically. For male patients with a pregnant partner, a condom should be used for
             contraception. For male patients with a non-pregnant female partner of child-bearing
             potential and woman of childbearing potential one of the following birth control
             methods with a failure rate of less than 1% per year when used consistently and
             correctly are recommended:

               -  Combined estrogen and progesterone containing hormonal contraception associated
                  with inhibition of ovulation given orally, intravaginally, or transdermally

               -  Progesterone-only hormonal contraception associated with inhibition of ovulation
                  given orally, by injection, or by implant

               -  Intrauterine device (IUD)

               -  Intrauterine hormone-releasing system (IUS)

               -  Bilateral tubal occlusion

               -  Vasectomized partner

               -  Sexual abstinence

                    -  Women of childbearing potential must have a negative pregnancy test (serum)
                       documented at screening and then negative serum or urine pregnancy testing
                       at day 1 of every treatment cycle (exception: negative pregnancy testing
                       within 21 days prior to cycle 1 day 1 [C1D1] is allowed)

        Exclusion Criteria:

          -  An additional validated oncogenic driver that could cause resistance to selpercatinib
             treatment (if known)

          -  Prior treatment with a selective RET inhibitor(s) (pralsetinib [BLU-667], including
             investigational selective RET inhibitor[s])

          -  Investigational agent or anticancer therapy (including chemotherapy, biologic therapy,
             or immunotherapy) within 5 half-lives or 3 weeks (whichever is shorter) prior to
             planned start of selpercatinib

               -  Exception: Patients with ATC

          -  No concurrent investigational anti-cancer therapy is permitted

          -  Major surgery (excluding placement of vascular access and diagnostic procedures)
             within 4 weeks prior to planned start of selpercatinib

               -  Exception: Patients with ATC

          -  Radiotherapy with a limited field of radiation for palliation within 1 week of the
             first dose of study treatment, with the exception of patients receiving radiation to
             more than 30% of the bone marrow or with a wide field of radiation, which must be
             completed at least 4 weeks prior to the first dose of study treatment

          -  Any unresolved toxicities from prior therapy greater than Common Terminology Criteria
             for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the
             exception of alopecia and grade 2, prior platinum therapy related neuropathy

          -  Symptomatic primary central nervous system (CNS) tumor, metastases, leptomeningeal
             carcinomatosis, or untreated spinal cord compression

               -  Exception: Patients are eligible if neurological symptoms and CNS imaging are
                  stable and steroid dose is stable for 14 days prior to the first dose of
                  selpercatinib and no CNS surgery or radiation has been performed for 28 days, 14
                  days if stereotactic radiosurgery (SRS)

          -  Patients with clinically significant active cardiovascular disease, Torsades de
             pointes, or history of myocardial infarction within 6 months prior to planned start of
             study treatment or prolongation of the QT interval corrected for heart rate using
             Fridericia's formula (QTcF) > 470 msec

          -  Patients with clinically significant active malabsorption syndrome or other condition
             likely to affect gastrointestinal absorption of the drug

          -  Use of a concomitant medication that is known to cause QTc prolongation

          -  Active uncontrolled systemic bacterial, viral, or fungal infection, or serious ongoing
             intercurrent illness, such as uncontrolled hypertension (systolic blood pressure [BP]
             >= 140 mmHg or diastolic BP >= 90 mmHg per CTCAE) or diabetes, despite optimal
             treatment. Screening for chronic conditions is not required

          -  Uncontrolled symptomatic hyperthyroidism or hypothyroidism

               -  Exception: Patients with papillary thyroid cancer (PTC)

          -  Uncontrolled symptomatic hypercalcemia or hypocalcemia

          -  Pregnancy or lactation

          -  Active second malignancy other than minor treatment of indolent cancers

               -  Exception: Patients with PTC or patients with stable pheochromocytoma in MEN2

          -  History of severe hypersensitivity (>= grade 3) to selpercatinib and/or any of its




12 Years - N/A

Accepts Healthy Volunteers



Mark Zafereo, 713-563-9683, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

M.D. Anderson Cancer Center

Study Sponsor

Mark Zafereo, Principal Investigator, M.D. Anderson Cancer Center

Verification Date

July 2022